Less than two years after Merrimack Pharmaceuticals Inc. won approval of Onivyde (irinotecan liposome injection) for second-line pancreatic cancer, pundits are weighing Paris-based Erytech Pharma SA's odds with eryaspase (Graspa), which has landed solid phase IIb results in the same indication: a 43 percent reduction in death risk.